This clinical trial is for men and women with unresectable glioblastoma or gliosarcoma at first or second recurrence. The combination of DNX-2401 and pembrolizumab could enhance the efficacy of treatment against these aggressive brain tumors.

**Key Eligibility**

- Open to men and women age 18 and older
- Diagnoses with glioblastoma or gliosarcoma at first or second recurrence
- Participants must have unresectable disease
- Detailed eligibility reviewed when you contact the study team

**To participate in this trial contact:**

Alyson Hignight | alh2031@med.cornell.edu
(212) 746-1788 | Reference IRB# 1602017004
Multi-center, open-label study of a conditionally replicative adenovirus with Pembrolizumab for recurrent Glioblastoma or Gliosarcoma

This clinical trial is for men and women with unresectable glioblastoma or gliosarcoma at first or second recurrence. The combination of DNX-2401 and pembrolizumab could enhance the efficacy of treatment against these aggressive brain tumors.

PHASE: 2

Reference IRB# 1602017004

For more information visit jcto.weill.cornell.edu

Weill Cornell Medicine

New York-Presbyterian

Joint Clinical Trials Office (JCTO)